Foresite Capital Management VI LLC Purchases Shares of 4,202,670 Alumis Inc. (NASDAQ:ALMS)

Foresite Capital Management VI LLC purchased a new stake in Alumis Inc. (NASDAQ:ALMS) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 4,202,670 shares of the company’s stock, valued at approximately $33,033,000. Alumis comprises approximately 14.7% of Foresite Capital Management VI LLC’s portfolio, making the stock its 2nd biggest position. Foresite Capital Management VI LLC owned 8.90% of Alumis as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wells Fargo & Company MN lifted its stake in Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after buying an additional 3,823 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Alumis during the fourth quarter valued at about $79,000. Marshall Wace LLP purchased a new stake in Alumis during the fourth quarter valued at about $108,000. XTX Topco Ltd purchased a new stake in Alumis during the fourth quarter valued at about $129,000. Finally, Mariner LLC purchased a new stake in Alumis during the fourth quarter valued at about $142,000.

Insider Transactions at Alumis

In other news, CEO Martin Babler bought 15,650 shares of the business’s stock in a transaction on Tuesday, April 1st. The shares were bought at an average cost of $6.44 per share, for a total transaction of $100,786.00. Following the completion of the acquisition, the chief executive officer now owns 106,454 shares in the company, valued at approximately $685,563.76. This trade represents a 17.23 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan Colowick bought 16,104 shares of the business’s stock in a transaction on Tuesday, April 1st. The stock was purchased at an average price of $6.97 per share, for a total transaction of $112,244.88. Following the completion of the acquisition, the director now owns 16,104 shares of the company’s stock, valued at approximately $112,244.88. This trade represents a ? increase in their position. The disclosure for this purchase can be found here.

Alumis Stock Performance

NASDAQ:ALMS opened at $4.28 on Monday. Alumis Inc. has a 12 month low of $3.18 and a 12 month high of $13.53. The company’s 50-day moving average price is $5.50 and its two-hundred day moving average price is $7.64.

Analysts Set New Price Targets

ALMS has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. HC Wainwright dropped their target price on Alumis from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, April 22nd. Finally, Oppenheimer initiated coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $25.86.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.